Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Torisel

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

- PMLiVE

Teva signs R&D alliance to pursue novel cancer drugs

Will work with Cancer Research on first-in-class oncology treatments

- PMLiVE

‘Biomedical Facebook’ launches to speed up cancer research

Europe's Granatum.org aims to connect pharma, academia and other research bodies

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

J&J completes Aragon deal as Seragon is born

Acquisition of cancer drug specialist secures promising new prostate cancer therapy

- PMLiVE

Bayer gets new Japanese approval for Stivarga

Additional licence covers drug's use in gastrointestinal stromal tumours

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

- PMLiVE

Pfizer sales dip as net income surges in Q2

Lipitor performance weighs heavy on the figures

- PMLiVE

GSK and Pfizer extend vaccine access programme

Pharma companies lower price of pneumococcal vaccines for developing nations

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links